Chronic kidney disease can have severe effects on growth in children, leading to short stature and problems with both physical and psychological health. Abnormally high or abnormally low bone turnover can increase the severity of growth retardation in children with kidney disease, so finding a normal balance is important. Recombinant human growth hormone can often help, but response is variable in children on dialysis.
To evaluate the direct effect of recombinant human growth hormone therapy on the skeleton in pediatric patients, Justine Bacchetta MD, PhD, Katherine Wesseling-Perry MD (David Geffen School of Medicine at UCLA) and their colleagues randomized 33 pediatric dialysis patients to therapy with or without growth hormone.
Among the major findings:
- Growth hormone therapy resulted in greater increases in height.
- Growth hormone enhanced bone turnover in patients with baseline low bone turnover, but it counteracted the bone-turnover lowering effects of vitamin D therapy in patients with high bone turnover.
- Parathyroid hormone values were similar in patients who received growth hormone compared with those who did not, despite marked differences in final rates of bone formation.
"Pediatric patients treated with growth hormone had better improvements in height than those on standard therapy. The therapy enhanced bone turnover in patients with baseline low bone turnover while not altering bone formation in patients with high bone turnover," said Dr. Wesseling-Perry. "Unfortunately, growth hormone interrupts the relationship between bone turnover and parathyroid hormone-a marker that is used to judge bone health in these patients-making it difficult to assess bone health by blood tests alone," she added.
The findings suggest that growth hormone may help treat poor growth and low bone turnover in children on dialysis. It may also improve growth in the children with high bone turnover, but it may not benefit their overall bone health.
Study co-authors include Beatriz Kuizon, MD, RenataPereira, PhD, Barbara Gales, RN, He-jing Wang, MD, Robert Elashoff, PhD, and Isidro Salusky, MD.
Disclosures: Isidro Salusky has received honoraria from Genzyme, Abbott, Johnson and Johnson, and Cytochroma.
The article, entitled "The Skeletal Consequences of Growth Hormone Therapy in Dialyzed Children: A Randomized Trial," will appear online at http://cjasn.asnjournals.org/ on April 4, 2013, doi: 10.2215/CJN.00330112.
The content of this article does not reflect the views or opinions of The American Society of Nephrology (ASN). Responsibility for the information and views expressed therein lies entirely with the author(s). ASN does not offer medical advice. All content in ASN publications is for informational purposes only, and is not intended to cover all possible uses, directions, precautions, drug interactions, or adverse effects. This content should not be used during a medical emergency or for the diagnosis or treatment of any medical condition. Please consult your doctor or other qualified health care provider if you have any questions about a medical condition, or before taking any drug, changing your diet or commencing or discontinuing any course of treatment. Do not ignore or delay obtaining professional medical advice because of information accessed through ASN. Call 911 or your doctor for all medical emergencies.
Founded in 1966, and with more than 13,500 members, the American Society of Nephrology (ASN) leads the fight against kidney disease by educating health professionals, sharing new knowledge, advancing research, and advocating the highest quality care for patients.